Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018

Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and
Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
Incidence of Breast Cancer Will Increase by 1.2 Percent Annually Through 2018
in the World's Major Markets, According to a New Report from Decision
Resources

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's
leading research and advisory firms for pharmaceutical and healthcare issues,
finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting
therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon
Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer
treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected
launches of three new therapies will drive sales of HER2-targeting agents to
grow by 3.3 percent per year from 2008 to 2018 in the United States, France,
Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Breast Cancer finds that significant
declines in sales in the hormonal therapy and chemotherapy segments of the
market will be offset by a 1.2 percent annual increase in breast cancer
incidence in the world's major markets and by the launch and uptake of
premium-priced agents. Emerging HER2-targeting therapies that are expected to
launch by 2018 include Roche/Chugai's Omnitarg, Roche's T-DM1 and Wyeth's
HKI-272.

The report also finds that sales of Roche/Chugai's Avastin for breast cancer
will increase by four percent from 2008 to 2018, largely owing to greater
uptake by patients with metastatic disease.

"Since its approval, Avastin has garnered substantial patient share in
metastatic breast cancer, particularly in the metastatic triple-negative and
metastatic HR-refractory treatment settings, where there is a significant need
for effective therapeutic options," said Decision Resources Analyst Niamh
Murphy, Ph.D. "However, many of the physicians we interviewed, particularly in
Europe, are not very enthusiastic about Avastin for breast cancer because they
consider its cost-benefit profile suboptimal."

According to the report, experts are enthusiastic about the launch and uptake
of a novel class of breast cancer therapies -- the poly ADP-ribose polymerase
(PARP) inhibitors. The PARP inhibitors represent a novel therapeutic strategy
in DNA-repair-deficient tumors, such as triple-negative breast cancer.

"PARP inhibitors, which include Sanofi-Aventis's BSI-201 and AstraZeneca's
olaparib, could dramatically improve prognoses for the woefully underserved
patient subgroups with DNA-repair-deficient tumors," Dr. Murphy said.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
ccomfort@dresources.com emarshall@dresources.com

SOURCE Decision Resources

Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com